Cidara Therapeutics, Inc.

NasdaqCM CDTX

Cidara Therapeutics, Inc. Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending September 30, 2024

Cidara Therapeutics, Inc. Return on Capital Employed (ROCE) is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.
  • Cidara Therapeutics, Inc. Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending September 30, 2022 was -124.92%.
Key data
Date Return on Capital Employed (ROCE) Interest Coverage Ratio Debt to Equity Ratio Return on Common Equity
Market news
SV Wall Street
NasdaqCM: CDTX

Cidara Therapeutics, Inc.

CEO Dr. Jeffrey L. Stein Ph.D.
IPO Date April 15, 2015
Location United States
Headquarters 6310 Nancy Ridge Drive
Employees 69
Sector Healthcare
Industries
Biotechnology Clinical Trials Pharmaceuticals Vaccines
Description

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.

StockViz Staff

February 6, 2025

Any question? Send us an email